Advertisement

‘Exciting’ milestone as weight-loss pills hit shelves

Kim Roberts is switching from weekly weight-loss injections to a daily Wegovy tablet. <i>Photo: supplied</i>

Kim Roberts is switching from weekly weight-loss injections to a daily Wegovy tablet. Photo: supplied

Kim Roberts has been giving herself weekly weight loss drug injections for the last three years, after a heart attack led to the discovery of a genetic cholesterol condition.

But now, the teacher and mother-of-six will be able to take the GLP-1 drug Wegovy in the form of a daily tablet.

“It will just fit in with what I do on a day-to-day basis,” she told AAP.

Wegovy became Australia’s first weight-loss tablet to be cleared by the Therapeutic Goods Administration earlier this month, with the appetite-suppressing medication hitting pharmacy shelves from Friday.

It works by mimicking the hormone naturally released by the gut after eating, regulating hunger and cravings.

It also improves outcomes for cardiovascular disease patients.

Roberts, 46, said the drug had helped her manage her elevated lipoprotein(a), a condition which heightens her risk of heart attack, stroke and heart disease.

It also helped her lose around 30 kilograms.

“I feel better. It’s also taught me how to eat better,” she said.

Like the injections, Wegovy tablets don’t come cheap. Photo: AAP

However, the Wegovy tablets – like the injections – are set to cost patients up to $5000 a year.

Roberts said the cost was a major consideration in taking the drug.

“I’ve got a very good job, so I’m lucky that I can afford it,” she said.

“It would be wonderful to see if it was reduced in price … so that more people can get the benefit from it.”

A second weight-loss pill, marketed as Foundayo, was also approved for sale in Australia in recent days.

Roberts’ doctor, Jason Kovacic, said he hoped the improved accessibility of weight-loss drugs, and more competition in the market, would push down prices.

The head of the Victor Chang Cardiac Research Institute also called for GLP-1 drugs to be added to the Pharmaceutical Benefits Scheme.

“What’s really exciting about these drugs is that this actually opens up a fourth treatable risk factor,” Kovacic told AAP.

“Previously, we’ve been able to treat blood pressure, cholesterol, and glucose. And with these drugs, we can now treat … overweight and obesity.”

The federal government is currently in negotiations with Wegovy’s manufacturer, Novo Nordisk, to bring it onto the scheme for a small cohort of patients.

It would bring the price down to $25 per script or $7.70 for concession card holders.

Kovacic said he expected to be inundated with requests from patients to be switched over to the pill form of the medication.

“The injections have been something that people have tolerated, but are really looking forward not having to do,” he said.

–AAP

Advertisement